Aeberli D, Leech M, Morand E F
Centre for Inflammatory Diseases, Monash Medical Centre, Locked Bag No 29, Clayton Melbourne 3168, Australia.
Rheumatology (Oxford). 2006 Aug;45(8):937-43. doi: 10.1093/rheumatology/kel142. Epub 2006 May 16.
Glucocorticoids (GCs) are widely used in the treatment of inflammatory diseases including rheumatoid arthritis (RA). Treatment with GC is associated with significant dose-dependent side-effects. The pro-inflammatory cytokine macrophage migration inhibitory factor (MIF) has emerged in recent years as a candidate factor which could regulate GC sensitivity. MIF is induced by GC, and is able to override anti-inflammatory actions of GCs. In this review, we summarize the pro-inflammatory actions of MIF with respect to RA, describe the interactions between MIF and GC and examine new evidence, which identifies MIF as a specific target for steroid sparing.
糖皮质激素（GCs）被广泛用于治疗包括类风湿性关节炎（RA）在内的炎症性疾病。使用GC进行治疗会产生显著的剂量依赖性副作用。近年来，促炎细胞因子巨噬细胞移动抑制因子（MIF）已成为可能调节GC敏感性的候选因子。MIF由GC诱导产生，并且能够抵消GC的抗炎作用。在本综述中，我们总结了MIF在RA方面的促炎作用，描述了MIF与GC之间的相互作用，并研究了将MIF确定为类固醇节约特异性靶点的新证据。
